Cerebral Therapeutics announces enrolment of first patient in phase 2b trial in epilepsy

Cerebral Therapeutics announced that the first patient has been enrolled in a Phase 2b study of intracerebroventricular drug delivery of the anti-seizure medication CT-010 in patients with medically refractory epilepsy.